Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioSyent to Present at 2017 Bloom Burton & Co. Healthcare Investor Conference

V.RX

TORONTO, ONTARIO--(Marketwired - April 24, 2017) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference on May 1st, 2017 at 3:00pm ET at the Sheraton Centre Toronto Hotel, Toronto, Ontario. Mr. René Goehrum, President and CEO, will present to investors an overview of BioSyent's business and corporate activities. Mr. Goehrum will also be available to meet with investors on a one-on-one basis during the conference on May 1st and 2nd. These one-on-one meetings can be requested by attendees through the online conference portal: http://www.bloomburton.com/conference/.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,472,453 shares issued and outstanding.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013
E-Mail: investors@biosyent.com
Web: www.biosyent.com